InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,283.40
(
0.11%
)
US TECH 100
18,124.40
(
0.53%
)
Dow Jones
38,571.03
(
-0.30%
)
Brent Oil
77.73
(
-0.53%
)
Bitcoin
69,239.98
(
0.63%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

micanwait

Send PM Follow Ignore
Followers 6
Posts 718
Boards Moderated 0
Alias Born 06/22/2011

micanwait

Re: Whosetosay post# 51860

Saturday, 07/26/2014 9:15:21 AM

Saturday, July 26, 2014 9:15:21 AM

Post# of 80490
2da --

Indeed, what oncologist would not opt to avoid mutations? It is the key.

I can't find a prior post from someone who has noted that AEs related to blood clots have dropped to zero since Ariad started better screening. If that is the case, pona should certainly be a front line candidate. You can see why Denner loves Iclusig. Add in off-label stuff, other applications etc.and we might have a real drug here.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up